ARHGDIB and AT1R autoantibodies are differentially related to the development and presence of chronic antibody-mediated rejection and fibrosis in kidney allografts by Betjes, M.G.H. (Michiel) et al.
Human Immunology 82 (2021) 89–96Contents lists available at ScienceDirect
www.ashi-hla.org
journal homepage: www.elsevier .com/locate /humimmResearch articleARHGDIB and AT1R autoantibodies are differentially related to the
development and presence of chronic antibody-mediated rejection and
fibrosis in kidney allograftshttps://doi.org/10.1016/j.humimm.2020.12.003
0198-8859/ 2020 The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author.
E-mail address: m.g.h.betjes@erasmusmc.nl (M.G.H. Betjes).Michiel G.H. Betjes a,⇑, Kasia A. Sablik a, Nicolle H.R. Litjens a, Henny G. Otten b, Annelies E. de Weerd a
aDepartment of Internal Medicine, Section Nephrology and Transplantation, Erasmus MC, University Medical Center, Rotterdam, Rotterdam, the Netherlands
b Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
a r t i c l e i n f o a b s t r a c tArticle history:
Received 28 October 2020
Revised 3 December 2020
Accepted 5 December 2020







Angiotensin II type 1-receptor
Rho GDP-dissociation inhibitor 2The role of non-HLA autoantibodies in chronic-active antibody-mediated rejection (c-aABMR) of kidney
transplants is largely unknown. In this study, the presence and clinical relevance of non-HLA autoanti-
bodies using a recently developed multiplex Luminex-based assay were investigated. Patients with a kid-
ney allograft biopsy at least 6 months after transplantation with a diagnosis of c-aABMR (n = 36) or no
rejection (n = 21) were included. Pre-transplantation sera and sera at time of biopsy were tested for
the presence of 14 relevant autoantibodies.
A significantly higher signal for autoantibodies against Rho GDP-dissociation inhibitor 2 (ARHGDIB)
was detected in recipients with c-aABMR as compared to recipients with no rejection. However,
ARHGDIB autoantibodies did not associate with graft survival. Levels of autoantibodies against angioten-
sin II type 1-receptor (AT1R) and peroxisomal trans-2-enoyl-CoA reductase (PECR) were increased in
recipients with interstitial fibrosis in their kidney biopsy. Only the signal for AT1R autoantibody showed
a linear relationship with the degree of interstitial fibrosis and was associated with graft survival.
In conclusion, anti-ARHGDIB autoantibodies are increased when c-aABMR is diagnosed but are not
associated with graft survival, while higher levels of AT1R autoantibody are specifically associated with
the presence of interstitial fibrosis and graft survival.
 2020 The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and
Immunogenetics. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. Introduction
Long-term graft loss of the kidney allograft has changed little in
the last decades and improving this outcome is considered an
unmet need [1]. Chronic-active antibody mediated rejection (c-
aABMR) is recognized as one of the major causes of graft loss in
the long term in recipients of a donor kidney [2,3]. The median
time to diagnosis is about 6 years with a broad range between
1 year to 15 years after kidney transplantation [4,5]. Histology
essentially shows signs of chronic microvascular inflammation
(glomerulitis and peritubular capillaritis) leading to endothelial
basal membrane duplication and finally interstitial fibrosis and
tubular atrophy [6]. The presence of serum anti-donor antibodies
is believed to be underlying the pathogenesis. A variable degree
of complement activation can be shown as C4d deposition along
the capillary walls and binding and activation of Fc-receptorbearing immune cells, notably monocytes and NK cells, results in
local production of inflammatory mediators like IL-6 [7,8].
Antibodies against donor tissue may consist of donor-specific
HLA-antibodies (DSA) or non-HLA antibodies, which both may be
already present before transplantation or arise as de novo antibod-
ies. However, in a substantial percentage of recipients with a diag-
nosis of c-aABMR no anti-HLA DSA can be detected. Clinical
presentation, renal histology and rate of graft loss is not different
between recipients with or without detectable anti HLA at time
of diagnosis [9,10]. Fluctuations in DSA serum concentrations and
antibody absorption by the donor kidney are possible explanations,
as well as antibodies directed against non-HLA antigens [11].
Recently, a multiplex luminex technique-based assay was devel-
oped for the detection of non-HLA antibodies against target pro-
teins, which were selected based on relevant published studies
[12]. In a large Dutch retrospective cohort study it was shown that
presence of antibodies against ARGHDIB prior to kidney transplan-
tation was an independent risk factor for long-term kidney allo-
graft survival [13]. In a subsequent study from Senev et al, the
Michiel G.H. Betjes, K.A. Sablik, Nicolle H.R. Litjens et al. Human Immunology 82 (2021) 89–96MFI level of ARHGBIB autoantibodies, particular in combination
with DSA, was significantly associated with the risk for graft failure
in patients with a histological diagnosis of AMBR but not in the
control group of non-ABMR patients [14]. In addition, ARGHDIB
antigen and mRNA showed increased expression in the kidney
with ABMR.
In the current study serum autoantibody levels at time of diag-
nosis of c-aABMR and before kidney transplantation were studied
in relation to Banff scores of the kidney biopsy, degree of intersti-
tial fibrosis and graft survival.
2. Material and methods
2.1. Study population
Kidney transplant recipients with a for cause kidney biopsy at
least 6 months post transplantation within the period June 2015-
January 2018 were included in this study (n = 68). No routine
HLA DSA screening protocol was present. The cause for biopsy
was progressive loss of graft function or proteinuria not otherwise
explained. The date of last follow-up was january 2020 yielding a
maximum follow-up time of 60 months. Recipients were diag-
nosed as having either c-aABMR (rejection group) or without any
sign of rejection but a variable degree of chronic damage (no rejec-
tion group, NR). Biopsies with another diagnosis (e.g. glomeru-
lonephritis, BK nephropathy, diabetic nephropathy or TCMR)
were excluded. Clinical and laboratory data were collected at time
of biopsy. Kidney biopsies were scored according to the Banff ’17
criteria by an experienced renal pathologist. Immunohistochemical
staining for C4d was not available in 1 patient. If the first 2 criteria
of the Banff were fulfilled than a diagnosis of c-aABMR histology(c-
aABMRh) was made, in accordance with recent publications
[4,5,14,15]. Chronic damage was assessed along the Banff criteria
for tubular atrophy, interstitial fibrosis, arteriolar hyalinosis and
vascular fibrous intimal thickening.
Allograft failure was defined by the need for starting dialysis
treatment or a kidney re-transplantation. The local medical ethical
committee approved the study (MEC-2015-222) and humans
involved in this study were treated in accordance with the Decla-
ration of Helsinki and the clinical and research activities being
reported are consistent with the Principles of the Declaration of
Istanbul as outlined in the ‘Declaration of Istanbul on Organ Traf-
ficking and Transplant Tourism’
2.2. Characterization of anti-HLA antibodies
All patients were transplanted ABO-blood group compatible
with a CDC negative crossmatch. All sera at time of diagnosis of
c-aABMR(h) were screened for the presence of donor-specific anti-
bodies against HLA (DSA) using the Lifecodes Lifescreen Deluxe
(LMX) kit, according to the manufacturer’s manual (Immunocor
Transplant Diagnostics Inc. Stamford, CT, USA). Samples were con-
sidered positive for either HLA class I (HLA-A or HLA-B or HLA-C) or
HLA class II (HLA-DQ or HLA-DR) antibodies were further analyzed
with a Luminex Single Antigen assay, using LABscreen HLA class I
and class II antigen beads (One Lambda Canoga Park, GA, USA).
All tested sera were heat-treated for 30 min at 56 Celsius to avoid
interference of complement in the Luminex assay.
An in house assay was developed for detection of a selection of
relevant non-HLA target proteins (n = 14), as has been described in
detail previously [12,13,16]. Target proteins were: agrin, adipocyte
plasma membrane-associated protein (APMAP), Rho GDP-
dissociation inhibitor 2 (ARHGDIB), Rho guanine nucleotide
exchange factor 6 (ARHGEF6), endorepellin, Lamin B1 (LNMB1),
BPI fold-containing family B member 1 (LPLUNC1), protein kinase
C zeta type (PRKCZ), tubulin beta-4B (Tubb4B), Angiotensin II type901-receptor (AT1R) and endothelin type A receptor (ETAR), vimen-
tin, peroxisomal trans-2-enoyl-CoA reductase (PECR) and phos-
pholipase A2 receptor (PLA2R).
AT1R and PECR were coupled directly with carboxylated Mag-
Plex Microspheres (Luminex Corp, Austin, TX). The other 12 of
the 14 proteins with a HaloTag to optimize antibody binding. The
HaloTag proteins were coupled via a HaloTag Amine (O4) Ligand
(Promega, Madison, WI) to the carboxylated MagPlex micro-
spheres. Transferrin (directly- or HaloTag-coupled) served as a
negative control, since it is ubiquitously present and no autoanti-
bodies against transferrin have been reported. Sera (1:25 dilution)
were incubated overnight with the microsphere mix. Next, R-
phycoerythrin-conjugated goat-anti human antibody was added.
After 30 min of incubation, wash buffer was added and samples
were measured on a Luminex 200 flow analyzer (Luminex Corp).
Transferrin (directly- or HaloTag-coupled) served as a negative
control. The data were expressed as mean fluorescence intensity
MFI and signal to background ratio (STBR) using the MFI for trans-
ferrin as the background signal.
2.3. Statistical analysis
Normally distributed data are expressed as mean +/ SD, non-
normally distributeddata asmedianwith25th and75thpercentiles.
A p-value of <0.05 was considered statistically significant. Differ-
ences between groups of non-normally distributed data were ana-
lyzed by the Mann-Whitney test and the Wilcoxon signed-rank
test for paired data. Correlations between clinical parameters (eGFR
(CKD-EPI formula) at diagnosis, time after transplantation and pres-
ence of DSA and non-DSA anti-HLA antibodies) and signals of
autoantibodies of interest were investigated. The signal intensity
of autoantibodies andBanff scores of chronic damagewere analyzed
in a dichotomous fashion (present or absent) and by exploring the
relation with the Banff score using ANOVA linear trend analysis.
Death-censored graft survival was assessed by Kaplan-Meier
analysis with log-rank statistics for difference between strata. Uni-
variate Cox regression analysis was performed to identify an asso-
ciation between the intensity of the autoantibody signals and graft
survival after biopsy-proven diagnosis. Crude MFI values normal-
ized by log transformation and/or STBR ratios were used as vari-
ables. Statistical analysis was performed with software IBM SPSS
statistics 21.3. Results
3.1. Patient characteristics
The clinical and demographical characteristics of the patients/
recipients are shown in Table1. The percentage of recipients with
a living donor kidney was about 70%. The c-aABMRh group versus
the no rejection (NR) group did not differ with regard to recipient
age at transplantation, donor age and the time of biopsy after
transplantation. Median follow-up after diagnosis was shorter in
the c-aABMRh group because of a higher rate of graft failure.
The c-aABMRh group more often had a positive PRA (>4%) at
time of transplantation, but similar median number of HLA mis-
matches as compared to the NR group. eGFR at time of biopsy
was similar for both groups but the c-aABMRh group had a signif-
icantly higher level of proteinuria.
3.2. ARHGDIB autoantibodies are significantly increased in cases with
c-aABMRh at time of diagnosis
The unadjusted MFI and STBR at time of diagnostic kidney
biopsy are shown for all autoantibodies in Table 2. Of note is that
Table 1







Male/female recipient 11/10 25/11 >0.1

















Graft survival censored for death at 3 year
follow up
88% 75% 0.01
PRA > 4% at time of transplantation 18% 50% 0.03
HLA mismatches median 4 3 >0.1
DSA present (%)** – 19 (53%) –
Non-DSA anti-HLA antibodies present (%) – 20 (56%) –
Re-transplantation (%) 20% 30% >0.1
Living kidney donor 80% 78% >0.1















* IQR: interquartile range.
** % of total cases within group.
Table 2
Non-HLA antibody mean fluorescence intensity and signal-to-background ratio at
time of diagnostic kidney biopsy.
no rejection (N = 21) c-aABMR (N = 36) p-value
Agrin
MFI*, median (IQR) 368 (213–521) 385 (271–487) 0.7
STBR** 0.95 (0.86–1.15) 1.03 (0.91–1.29) 0.4
APMAB
MFI 347 (285–530) 409 (336–586) 0.2
STBR 1.02 (0.96–1.19) 1.17 (0.96–1.62) 0.08
ARGHDIB
MFI 694 (369–1363) 912 (642–2422) 0.03
STBR 1.17 (0.87–1.74) 2.08 (1.31–3.99) 0.04
ARHGEF
MFI 375 (272–562) 418 (298–595) 0.6
STBR 1.17 (0.97–1.34) 1.17 (0.97–2.45) 0.7
AT1R
MFI 1967 (1271–3867) 2044 (1400–4458) 0.7
STBR 8.7 (6.6–14.6) 10.0 (6.9–24.3) 0.3
Endorepellin
MFI 361 (259–502) 398 (291–3532) 0.4
STBR 1.05 (0.93–1.16) 1.05 (0.92–1.49) 0.4
ETAR
MFI 402 (269–401) 374 (279–577) 0.5
STBR 1.13 (0.95–1.46) 1.14 (0.91–1.30) 0.5
LMNB1
MFI 421 (289–589) 435 (305–609) 0.4
STBR 1.12 (0.99–1.33) 1.19 (1.05–1.37) 0.4
LPLUNC1
MFI 392 (278–579) 422 (296–607) 0.5
STBR 1.15 (1.02–1.22) 1.12 (1.00–1.44) 0.5
PECR
MFI 851 (584–1878) 626 (480–1040) 0.3
STBR 3.34 (2.52–5.45) 3.23 (2.26–4.61) 0.8
PLA2R1
MFI 439 (279–539) 402 (290–528) 0.9
STBR 1.05 (0.92–1.29) 1.02 (0.92–1.27) 0.8
PRKCZ
MFI 475 (268–617) 458 (376–668) 0.7
STBR 1.24 (1.12–1.43) 1.28 (1.16–1.60) 0.2
Tubb4B
MFI 373 (284–559) 465 (333–658) 0.13
STBR 1.16 (1.01–1.25) 1.36 (1.06–1.68) 0.2
Vimentin
MFI 393 (239–620) 374 (280–526) 0.8
STBR 1.07 (0.91–1.13) 1.00 (0.86–1.30) 0.8
* IQR: interquartile range, MFI: mean fluorescence signal, STBR:signal to back-
ground ratio.
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and STBR for ARHGDIB autoantibodies were significantly higher
in the c-aABMRh group (Table 2 and Fig. 1). The median signal of
ARHGDIB autoantibodies was significantly higher at time of biopsy
versus pre-transplantation in the c-aABMRh group (MFI 912 vs
694, p = 0.03 and STBR 2.08 vs 1.17, p = 0.04), but not in the NR
group (Fig. 1 and Supplemental Fig. 1). The median MFI for ARHG-
DIB antibodies was similar between both groups at time of kidney
transplantation.
Previous reports showed a relation between a high MFI for
ARHGDIB and increased risk for respectively graft loss and ABMR,
using the same autoantibody assay [14]. Using a cut off for the
MFI for ARGHDIB above 1000 (corresponding to the median MFI
level, Fig. 1) or below or above the median STBR (median = 2, data
not shown) did not reveal a difference in graft survival in the c-
aABMRh group. In addition, we could not find any association
between MFI for ARHGDIB (or any other auto-antibody) and the
presence of DSA or non-DSA HLA antibodies (data not shown).
PECR (Fig. 2A, Supplemental Fig. 1) and AT1R (Fig. 2B, Supple-
mental Fig. 1) autoantibodies increased significantly over time
but with no apparent differences between both the NR and c-
aABMRh groups. The other autoantibodies showed a remarkable
stable median signal, comparing time at transplantation with time
at biopsy, 40–50 months post-transplantation (Supplement Fig. 2).
Autoantibodies to every target protein tested, did not correlate sig-
nificantly with any other clinical or demographical parameter as
shown in Table 1. In addition, MFIs of auto-antibodies did not cor-
relate with presence of vascular inflammation in the c-aABMR
biopsies.3.3. PECR and AT1R autoantibodies associate with interstitial fibrosis
and graft survival
The signal strength of the autoantibody panel was related to the
Banff scores for chronic damage. Only the PECR and AT1R autoan-
tibodies showed an association with the score for interstitial fibro-
sis with no significant difference between c-aABMRh and NR.
Recipients with any degree of interstitial fibrosis in the kidney
biopsy revealed a higher median MFI for PECR and AT1R as com-
pared to patients without interstitial fibrosis in their biopsies91(Fig. 2). Of note, the pre-kidney transplantation levels were already
increased in patients who developed interstitial fibrosis later on in
their kidney biopsies, but remained low in patients without inter-
stitial fibrosis. Only the MFI of AT1R autoantibodies showed a sig-
nificant association with the degree of interstitial fibrosis, with a
linear progression in median levels of MFI (p = 0.02, Fig. 3). There
was no correlation between MFI levels for PECR and AT1R (data
not shown).
The median MFI level for PECR and AT1R was used to divide
recipients in low versus high autoantibody levels. Only high versus
low MFI of AT1R showed a significant difference in graft survival in
c-aABMRh (Fig. 4). Graft survival censored for death at 3 years was
95% in the AT1R low-group and 70% in the AT1R high-group. By
Cox regression, a higher hazard ratio for graft failure after diagno-
sis of c-aABMRh was found in relation to signal strength of ARHG-
DIB autoantibodies at time of biopsy (HR 1.57, p = 0.05 for log2
normalized MFI and HR 1.04, p = 0.014 for STBRs). Although hazard
ratios in the same range as time of biopsy were found for pre-
kidney transplant values of ARGHDIB autoantibodies, this associa-
tion did not reach statistical significance (data not shown).
The incidence of graft loss in the NR group was to low (n = 4) for
meaningful analysis but 3 out of 4 graft losses occurred in the AT1R
high group.
Fig. 1. Mean fluorescence intensity (MFI) for ARHGDIB autoantibodies for cases with a diagnosis of c-aABMR or no rejection (NR) before kidney transplantation (pre-KT) or at
time of kidney biopsy (post-KT). The dotted horizontal line is the median MFI for the negative control (transferrin microbeads). Only p-values < 0.05 for comparison between
groups are shown. The lower panel shows graft survival after the biopsy-proven diagnosis of c-aABMR according to the level of ARHGDIB autoantibodies (above or below
median MFI).
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The results of this study show that using a multiplex autoanti-
body assay, the MFI of 3 out of 14 selected target proteins showed a
relation with either a diagnosis of c-aABMR or interstitial fibrosis
and graft survival. Autoantibodies against ARHGDIB were exclu-
sively increased at time of biopsy in the cases diagnosed with c-
aABMRh while the MFI remained stable in the cases without rejec-
tion. The levels of AT1R and PECR autoantibodies were specifically
related to the presence of interstitial fibrosis in the kidney biopsy
and AT1R autoantibodies also with graft survival. These associa-
tions are of interest and appear to be specific, as MFIs of the
autoantibodies to 11 other target proteins remained remarkably
stable in both patient groups.
This study shows for the first time an association between
ARHGDIB autoantibodies and a diagnosis of c-aABMR. The first
publication with the multiplex assay used in this study found that
increased MFI for ARHGDIB pre-kidney transplantation was associ-92ated with decreased graft survival, independent of the presence of
DSA [13]. The chosen cut off for both unadjusted MFI and STBR was
high (the top 2.9%) and there was no information about the cause
of graft loss. In a completely different cohort of patients, Senev
et al. showed that cases of early ABMR had a significantly higher
MFI for ARHGDIB at time diagnosis [14]. In addition, a high MFI
(defined as > 1000), particular in association with the presence of
DSA, was an independent risk factor for kidney graft loss. Of inter-
est, the ARHGDIB protein was expressed in relevant kidney cells
(e.g.endothelial cells) [13,14] and intrarenal mRNA levels were
sharply increased in cases of ABMR [14].
Our findings constitute the second cohort of cases in which a
relation was found between ARGHDIB and humoral rejection,
although the number of cases is smaller and includes patients with
chronic AMBR long after transplantation. This is a relevant differ-
ence as the previous publications in particular showed an early
effect on graft survival of ARGHDIB autoantibodies. Time of diagno-
sis, in particular early acute ABMR versus late c-aABMR, has a dif-
Fig. 2. The mean fluorescence intensity (MFI) for autoantibodies against PECR (A) and AT1R (B) before kidney transplantation (pre-KT) or at time of kidney biopsy (post-KT) in
relation to the presence or absence of interstitial fibrosis (IF) in the kidney biopsy. The dotted horizontal line is the median MFI for the negative control (transferrin
microbeads). Only p-values < 0.05 for comparison between groups are shown.
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a risk factor for decreased graft survival [17,18]. For instance, in
cases of c-aABMR the presence of DSA is not associated with graft
survival [9,10]. Therefore, the lack of association of autoantibodies
for ARGHDIB and graft survival after c-aABMR as found in this
study is not necessarily in contradiction with the results of the
other studies. A possible scenario could be that pre-transplant
ARGHDIB autoantibodies aggravate an inflammatory response
when the intracellular located protein in the damaged endothelial
cells is exposed during acute ABMR. ARHGDIB may activate the
humoral immune response as it is recognized as a minor alloanti-
gen [19]. In contrast, c-aABMR is a relatively slow immunological
process evolving over a number of years and this may lead to a
mild increased exposure of ARHGDIB to the immune system and
subsequent increase of autoantibody titers. The increase in titers,
as reflected in the mild increase in MFI for ARHGDIB observed in
this study, is then a result of the ongoing chronic inflammation
but does not foster the process itself and hence does not contribute
to graft loss. Alternatively, increasing ARHGDIB auto-antibody
levels could potentially be involved in leading to chronic ABMR,
which once present, is a risk factor for allograft loss.93A novel finding was the relation between MFI levels for PECR
and AT1R and interstitial fibrosis in the kidney biopsy. This asso-
ciation was relatively weak for PECR autoantibodies and did not
translate in a clinical relevant end-point like graft survival. This
is important, as argued before in a previous publication, autoan-
tibodies can be detected for many proteins and a sensible cut-
off needs to be defined, preferably based on clinical significance
[16].
Of interest is that several studies have shown a relation
between AT1R autoantibodies and graft loss but not in relation to
the degree of fibrosis as shown in this study [20–23].
The level of AT1R autoantibodies was significantly lower and
close to the MFI of the negative control in recipients with no inter-
stitial fibrosis in their renal biopsies. In addition, the MFI increased
significantly from pre-transplant to time of biopsy in the cases
with interstitial fibrosis but remained low in the cases with now
interstitial fibrosis. Therefore, a high MFI for AT1R autoantibodies
appeared to have a strong negative predictive value for the out-
come ‘‘no interstitial fibrosis” in the allograft kidney even when
c-aABMR is the underlying pathology. In combination with the
association of MFI levels and graft survival, these findings argue
Fig. 3. Tukey box plots of the MFI values for PECR and AT1R in groups of cases ranked according to the degree of interstitial fibrosis (IF) in the kidney allograft biopsy at time
of diagnosis. MFI values before kidney transplantation (pre-KT) or at time of kidney biopsy (post-KT) are shown separately. According to the Banff criteria the degree of IF is
scored as absent (n = 4), mild (<25%, n = 25), moderate (25–50% IF, n = 16) and severe (>50% IF, n = 4).
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gression of interstitial fibrosis. AT1R is broadly expressed in virtu-
ally all cells in the renal tissue including vascular endothelial cells,
vascular smooth muscle cells but also inflammatory cells. AT1R-
antibodies exert an allosteric, agonistic effect on the receptor and
produce a sustained activation. This may lead to graft injury by
persistent vasoconstriction and triggering inflammation, fibrosis,
thrombosis and vascular remodeling [24]. The pathophysiological
chain of events is likely clinically important as a number of studies
have indicated an increased risk for kidney graft loss in the
presence of increased titers of pre-transplantation AT1R-
antibodies [25].
Of note, the MFI values for AT1R in the kidney transplant recip-
ients fall in the range of the MFI in healthy individuals [12]. There-
fore, it seems likely that these autoantibodies only are pathogenic
when other factors are active that initiate and promote interstitial
damage. Most likely, in c-aABMR the initial damage to the kidney is
caused by anti-donor specific antibodies such as anti-HLA antibod-
ies which cause activation of and damage to the microvasculature,
followed by tubular atrophy and interstitial fibrosis. In other cases
there may be a damage-initiating role for prolonged calcineurin
inhibitor use.
Along the same line of reasoning for ARHGDIB autoantibodies,
this will also be a relatively slow immunological process, but in
contrast to the ARHDIB target the AT1R protein is constitutively
expressed on the cell surface of e.g. renal tubular and endothelial
cells [26] and cell death is not a prerequisite for antigen exposure.94Although the results of this study need to be confirmed in a
large cohort, the data are intriguing and indicate that autoantibod-
ies may be involved in the pathogenesis of interstitial fibrosis. This
is in cases of c-aABMR highly relevant as the degree of interstitial
fibrosis in the renal biopsy has consistently been found to be the
only histological score predicting progression to graft failure
[9,15,27].
There are several limitations of the present study which should
be recognized. The number of cases is relatively small and the
study design does not include serial kidney biopsies over time with
serum sampling. The latter could have given more insight into the
possible cause and effect relation between the appearance of
ARGHDIB and AT1R antibodies and intragraft pathology. Neverthe-
less, the findings are in support of results of previous studies which
indicated a pathogenic role of these autoantibodies in graft injury
in other conditions than c-aABMR.
In conclusion, ARHGDIB antibodies are specifically increased
over time after transplantation in cases of c-aABMR but do not
affect graft survival. Instead AT1R autoantibodies are associated
with interstitial fibrosis and of clinical relevance for graft
survival.Funding sources
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Fig. 4. Graft survival after diagnosis of c-aABMR for cases with high (n = 19) or low (n = 17) MFI for AT1R (A) or high (n = 17) or low (n = 19) MFI for PECR (B) autoantibodies
based on the median MFI.
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